After 1 year of follow-up, patients on HAART with a baseline viral load (VL) of <20 copies/ml showed significantly lower odds of virological rebound to two consecutive VLs of >50 copies/ml than those with baseline VLs of 20 to 39 and 40 to 49 (P < 0.001). The time to virological rebound was also significantly shorter (P < 0.001) for the groups with baseline VLs of 20 to 39 and 40 to 49.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647906 | PMC |
| http://dx.doi.org/10.1128/JCM.00100-13 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding human papillomavirus vaccine response and efficacy in people living with HIV: A systematic mixed studies review and meta-analysis.
PLOS Glob Public Health
December 2024
Department of International Health, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Coinfection with human papillomavirus (HPV) and HIV compounds the risks of developing cervical, anal, and HPV-associated oral neoplasia. Safe prophylactic vaccines are available to prevent HPV infections in people with HIV(PWH). Yet, vaccine efficacy and duration of protection remain questionable.
View Article and Find Full Text PDFGraft-derived cell free DNA: used for assessment of early graft status and its implications for long-term kidney function.
Front Physiol
November 2024
Clinical Immunology Translational Medicine Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Background: The long-term graft survival is closely related to its early status, yet the indices for assessing the early graft status are complex and lack quantitative values. The aim of this study is to investigate the potential of GcfDNA as a comprehensive, non-invasive, convenient, and quantifiable indicator for evaluating early graft status.
Methods: In this study, 138 recipients who underwent primary kidney transplantation were enrolled.
Bioinspired designer DNA NanoGripper for virus sensing and potential inhibition.
Sci Robot
November 2024
Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
DNA has shown great biocompatibility, programmable mechanical properties, and precise structural addressability at the nanometer scale, rendering it a material for constructing versatile nanorobots for biomedical applications. Here, we present the design principle, synthesis, and characterization of a DNA nanorobotic hand, called DNA NanoGripper, that contains a palm and four bendable fingers as inspired by naturally evolved human hands, bird claws, and bacteriophages. Each NanoGripper finger consists of three phalanges connected by three rotatable joints that are bendable in response to the binding of other entities.
View Article and Find Full Text PDFA hand-held in-situ nucleic acid detection device based on dual-function GHz acoustofluidic resonator.
Biosens Bioelectron
January 2025
State Key Laboratory of Precision Measuring Technology and Instruments, Tianjin University, Tianjin, 300072, China. Electronic address:
Microfluidic-based nucleic acid testing (NAT) has been proven as an alternative approach for in-situ and rapid NA detection. However, these on-chip methods still require complex peripherals, which contradict the purpose of point-of-care (POC) applications. One of the major challenges is the integration of NA purification and amplification in a miniaturized setup with high mass and heat transfer efficiency.
View Article and Find Full Text PDFZiresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection.
N Engl J Med
September 2024
From the Department of Respiratory Medicine (S.Z.), Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, National Clinical Research Center for Respiratory Diseases (S.Z., X.N.), National Center for Pediatric Cancer Surveillance, Key Laboratory of Major Diseases in Children, Ministry of Education (X.N), and the Department of Pediatric Medicine, Peking University Third Hospital (W.Z.), Beijing, the Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang (Y.S.), the Department of Pediatric Respiratory Medicine, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine (Y. Yin), the Department of Pulmonology, Shanghai Children's Hospital, and the School of Medicine, Shanghai Jiao Tong University (X.D.), and Shanghai Ark Biopharmaceutical (X.Z., T.J., Y.W., G.Z., K.R., J.Z.W.), Shanghai, the Department of Respiratory Medicine, Tianjin Children's Hospital, Machang Campus (Y. Zou), the Department of Respiratory Medicine, Tianjin Children's Hospital, Longyan Campus (Y.X.), and Tianjin University (Y. Zou, Y.X.), Tianjin, Children's Medical Center, Hunan Provincial People's Hospital, Changsha (L.Z.), the Departments of Respiratory Medicine and Pediatric Infectious Diseases, Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou (Hailin Zhang, Y.C.), the Department of Pediatrics, Sanya Central Hospital, Hainan Third People's Hospital, Sanya (Hua Zhang), the Department of Pediatric Respiratory Medicine, Children's Hospital of Nanjing Medical University (D.Z.), and the Department of Pediatric Medicine, First Affiliated Hospital with Nanjing Medical University (R.D.), Nanjing, the Department of Pediatrics, Women and Children's Hospital, and the School of Medicine, Xiamen University (T.S.), and the Department of Pediatric Respiratory Medicine, First Affiliated Hospital of Xiamen University (Y. Yang), Xiamen, the Department of Pediatrics, Zhongshan Women and Children's Hospital-Zhongshan Boai Hospital, Zhongshan (D.H.), the Department of Pediatric Respiratory Medicine, Jiangxi Provincial Children's Hospital, Nanchang (Q.C.), the Department of Pediatric Respiratory Medicine, Liaocheng People's Hospital, Liaocheng (Q.Y.), the Department of Respiratory Medicine and Clinical Allergy Center, Wuxi Children's Hospital, Wuxi (L.L.), the Department of Pediatric Respiratory Medicine, Children's Hospital, Zhejiang University School of Medicine, Hangzhou (Z.C.), the Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Chongqing (E.L.), the Department of Pediatric Respiratory Medicine, Women and Children's Medical Center Affiliated to Guangzhou Medical University, Guangzhou (L.D., W.J.), the Department of Pediatric Respiration, Children's Medical Center, First Hospital of Jilin University, Changchun (H.C.), the Department of Pediatrics, First Affiliated Hospital of Guangxi Medical University, Nanning (G.N.), the Department of Pediatric Respiratory Medicine, Third Affiliated Hospital of Zhengzhou University (X.W.), and the Respiratory Department, Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, and Zhengzhou Children's Hospital (Z.S.), Zhengzhou, the Department of Respiratory Medicine, Shenzhen Children's Hospital, Shenzhen (Y. Zheng), the Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan (X.L.), the Department of Respiratory Medicine, Children's Hospital of Soochow University, Suzhou (C.H.), and the Department of Pediatric Respiratory and Immunology Medicine, West China Second University Hospital, Sichuan University, Chengdu (H.L.) - all in China.
Background: Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatment of infants hospitalized with RSV infection.
Methods: In a phase 3, multicenter, double-blind, randomized, placebo-controlled trial conducted in China, we enrolled participants 1 to 24 months of age who were hospitalized with RSV infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!